Downloading...
Download

FNMA

A look at Fannie Mae's long term rangeFannie Mae is setting up to be an interesting rectangular chart pattern. At some point FNMA will breakout and it'll be a high probability trade. Until then, the range lows offer an interesting long set-up with targets at the top of the range. This could take 2-5 years before breaking out (or less/more). From 1970 - 1986, FNMA did nothing except trade in a range before finally breaking out. Just a good one to keep an eye on, potentially a good indicator for the broader market as well - everytime Fannie Mae hit the lows of the range the broader market was a great buy. Percentage increase from the lows of the range generated a strong average return since 2013
OTC:FNMA
by Lanmar
$FNMA/$FMCC Riding On Momentum From 2 Catalysts;Long Road AheadBoth Fannie Mae ( FNMA ) and Freddie Mac ( FMCC ) are rocking and rolling. Mnuchin's interview paired with the court of appeals' move against the Gov't have sparked more interest here. This is great and another potential catalyst today could add fuel to the fire. HOWEVER, is there a motion likely before the election? I think the jury is still out on that front. We've got the election year to think about as well. My guess is short term momentum and hopefully, it retraces back to a higher support than its previous resistance range. " So, are FMCC stock and FNMA stock penny stocks to buy or should you avoid them like the plague? In my opinion, there still needs to be some diligence had right now and don’t throw caution to the wind either...Should a Democrat beat the current incumbent, this whole “to do” may be scrapped entirely. Even though things are exciting now, make sure to keep tabs on the underlying risks and learn how to manage should those materialize...At the end of the day, if an overhaul does happen, Congress will lead negotiations. All these points mentioned would be up for discussion. Some of the more conservative ideas would most likely get taken out of the running. So, keep in mind that there are many unknowns, still. The fact of the matter is that these two penny stocks will remain under close scrutiny for the foreseeable future; this week being the next potential milestone to keep an eye on. " Source - The Best Penny Stocks To Buy This Month? FMCC & FNMA
OTC:FNMA
by PennyStocks101
Does FNMA Have Enough juice To Keep Going?At this point FNMA might not be all speculation. "This latest plan is to return the two back to private hands. But as part of the plan, there would be a Treasury backstop in place. But this hasn’t come without pushback. Senate Banking Committee Senator Sherrod Brown has issues with this plan. The concern stems from possible risks that could arise by giving up control." - PennyStocks.com, 2 Penny Stocks To Buy Or Avoid This Month: FNMA & FMCC I think the government angle is something to pay attention to right now, personally. The closer a decision comes, the less "technical" and the more "headline" risk will play a factor.
OTC:FNMA
by PennyStocks101
$USRM Alerted from .012 Currently on 3rd Major Breakout Setup$USRM is currently awaiting RMAT designation which approved (And there is a 90% or higher chance it will) gives it similar qualities as Breakthrough Therapy, Accelerated Approval, and Priority Review. Basically, they can provisionally approve the drug or device for marketing and then provided the drug or device proves safe and reasonably effective, they will gain full approval - generally within 6 months. Other DD: 1. Institutional Loading 2. Multiple Patents 3. Nice ER that showed substantial profits 4. PreClinical Study Results Anyday 5. Form 4s filed by insiders 6. Uplistment
OTC:USRMLong
by StockGuild
$IDXG On The Run Again and this time it will be sustainedLet's recap $IDXG CC: 1. New York State and AETNA approvals of ThyraMIR®, microRNA assay 2. Talked about the Debt being restructured 3. No more offerings 4. Reduced operating costs 5. Talks of doing business with their BarreGen model 6. Talks of partnering with another bio he didn't discuss. 7. EPS value of $3.25 vs -($12.04) same quarter last year 8. Sales of $3.122 million. 9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it. 10. 64% of the S/S is SHORT 11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt 12. Revenue increased 39% Also most importantly the Patent Approval!!! $IDXG European Patent Decision data.epo.org ALSO FULL YEAR HIGHLIGHTS READ HERE: ih.advfn.com
ILong
by StockGuild
My First Chart on $NSAV No R/S and Merger News/Acquisitions$NSAV Catalysts: 1. No R/S Announced 2. Reduction of A/S 3. Company merging with $CHIF to create a large MJ Recreational Spa and Resort at Naomi Villages in Colorado 4. Acquisition News on the horizon 5. Medical Cannabis Technology Business Announced Chart: Right now there was massive volume on Friday after no R/S was announced by the CEO in addition to the MJ merger news that was announced a few days before that. He also said that there will be more updates available and audited Fins to be announced soon as well.
OTC:NSAVLong
by StockGuild
1
$ENDV Update on Upcoming Catalysts and Pennant Breakout$ENDV Upcoming Catalysts: 1. Pre-Clinical Studies To Be Completed in first quarter of 2017 2. Application for IND Orphan Drug Status for its Cytotronics Product 3. Over 20 Patent Applications OWNED by the CEO and the Company 4. 10 Form 4s filed since Dec 2016 for Insider purchases of stock 5. A "Strategic Healthcare" Institutional Investor has Ponied up $15 mil to buy back Converts 6. Company paying off the rest of its debt with $2.2 million 7. Uplistment to a "National" exchange being considered 8. Has won their injunction against Kodiak Capital and other Financiers for diluting the stock Chart: There is now a clear pennant forming on the chart, support has held tremendously and the RSI and Fibs have reset to levels corresponding with a second major move up. All marks are checked and it looks ready. Pre-Clinical trials expected in the first quarter of this year.
OTC:ENDVLong
by StockGuild